ArticleMedicine2026
Immune cells and rheumatic heart disease: A 2-sample and Bayesian weighted Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Using Mendelian randomization (MR) analysis to explore the immune cells involved in rheumatic heart disease (RHD). We conducted a bidirectional 2-sample MR study to screen the causal effects of 731 immune cell phenotypes on RHD. MR analysis was performed using regression models including inverse variance weighting, MR-Egger method, simple mode method, weighted median method, and weighted mode method. At the same time, heterogeneity tests, horizontal pleiotropy analysis, and sensitivity analyses were performed to verify the reliability of the MR results. Finally, to estimate causal effects under multiple hypotheses and improve the reliability of causal inference, we used the Bayesian weighted Mendelian randomization method to validate the results of the MR study. First, the results of MR showed that there was a causal relationship between 10 immune cell phenotypes and RHD, among which CD19 on CD20-, HVEM on TD CD4, CD40 on monocytes, CD45 on CD33- HLA DR-, CD11b on CD33br HLA DR+, CD14dim were risk factors for RHD, and CD24 on IgD+, CD24+, CD38 on CD3-, CD19-, CX3CR+, and CX3CR+. CD19-, CX3CR1 on CD14- CD16+ monocyte, CD14 on CD33dim HLA DR+, CD11b+, SSC-A on lymphocyte is a protective factor for RHD. Second, the results of reverse MR showed that RHD was not the influencing factor of the 10 positive immune cell phenotypes screened. Third, Bayesian weighted Mendelian randomization excluded CD40 on monocytes and CX3CR1 on CD14- CD16+ monocyte. The remaining results were the same as those of the 2 samples for MR analysis. This study confirmed the close relationship between immune cells and RHD through genetics. This study confirms the close association between immune cells and RHD by genetic means and provides a reference for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.